Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(147 produtos)
- Bcr-Abl(103 produtos)
- EGFR(572 produtos)
- FAK(71 produtos)
- FLT(91 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(169 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(87 produtos)
- Src(80 produtos)
- Syk(37 produtos)
- Trombina(47 produtos)
- VDA(2 produtos)
- VEGFR(262 produtos)
Exibir 6 mais subcategorias
Foram encontrados 1522 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
EGFR-IN-144
<p>EGFR-IN-144 (Compound 4B) inhibits EGFR (IC50=0.639 µg/mL) and tubulin polymerization (IC50=7.339 µg/mL). It exhibits cytotoxicity in various cancer cells with a GI50 at the nanomolar level. EGFR-IN-144 reduces the expression of mTOR, TNF-α, and IL-6, causes G1/S phase cell cycle arrest, and induces apoptosis.</p>Fórmula:C20H17Cl2N3O3Cor e Forma:SolidPeso molecular:418.273MET/PDGFRA-IN-2
<p>MET/PDGFRA-IN-2 (compound 8h) serves as an inhibitor of MET and PDGFRA proteins, promoting apoptosis in cells and impeding the proliferation of MET-positive</p>Fórmula:C29H29N7OPureza:98%Cor e Forma:SolidPeso molecular:491.59MTX-241F
<p>MTX-241F, a selective small molecule inhibitor, targets members of the EGFR and PI3 kinase families.</p>Fórmula:C20H14ClFN6Pureza:98%Cor e Forma:SolidPeso molecular:392.82ALK-IN-13
CAS:<p>ALK-IN-13 is an ALK inhibitor.</p>Fórmula:C29H39ClN7O2PCor e Forma:SolidPeso molecular:584.1Axltide
CAS:Axltide mimics mouse Insulin receptor substrate 1, amino acids 979-989 with sequence KKSRGDYMTMQIG.Fórmula:C63H107N19O20S2Pureza:98%Cor e Forma:SolidPeso molecular:1514.77DC-Srci-6649
CAS:<p>DC-Srci-6649 is a potent and selective inhibitor of c-Src kinase, effectively blocking its phosphorylation and stabilizing it in an inactive conformation.</p>Fórmula:C20H22Cl2N2O2SCor e Forma:SolidPeso molecular:425.37DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Cor e Forma:Odour SolidPROTAC FLT-3 degrader 1
CAS:<p>PROTAC FLT-3 degrader 1 is a PROTAC FLT-3 degrader of internal tandem duplication (ITD)(IC50 0.6 nM),with anti-proliferative activity.</p>Fórmula:C52H61N9O9S2Pureza:98%Cor e Forma:SolidPeso molecular:1020.23BW710
<p>BW710 is an orally active inhibitor specifically targeting fibroblast growth factor receptor 2 (FGFR2). It effectively inhibits the proliferation of BaF3-FGFR2 cells with an IC50 value of 2.8 nM. BW710 completely suppresses FGFR2 enzymatic activity and demonstrates selectivity among 75 tyrosine kinases, including FGFR1, FGFR3, and FGFR4, at a 1 μM concentration. Additionally, BW710 impedes FGFR2 signaling and selectively inhibits the proliferation of cancer cells driven by FGFR2. It exhibits promising pharmacokinetic properties, with an oral bioavailability of 29% in mice.</p>Fórmula:C28H29FN6O2SCor e Forma:SolidPeso molecular:532.63Duligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Pureza:95% - 95%Cor e Forma:LiquidSJ988497
CAS:<p>SJ988497: PROTAC JAK2 degrader, inhibits CRLF2r cell growth, degrades GSPT1, combines Ruxolitinib, linker, Pomalidomide; researched for ALL.</p>Fórmula:C36H36N10O5Cor e Forma:SolidPeso molecular:688.74Anticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Cor e Forma:Odour SolidPROTAC EGFR degrader 8
CAS:<p>PROTAC EGFR degrader 8 (T-184) is a PROTAC that selectively degrades the epidermal growth factor receptor (EGFR) with a DC50 of 15.56 nM in HCC827 cells.</p>Fórmula:C40H46ClN11O5Pureza:98%Cor e Forma:SolidPeso molecular:796.32Src Inhibitor 4
<p>Src Inhibitor4 (Compound 18) is a derivative of KX-01 and functions as a Src inhibitor. It effectively disrupts tumor cells, damages microtubules, and induces cell cycle arrest, apoptosis, and immunogenic cell death. After introducing phenol or aniline functional groups, Src Inhibitor4 serves as a payload conjugation site for antibody-drug conjugates, showcasing antitumor activity.</p>Fórmula:C33H34N4O3Cor e Forma:SolidPeso molecular:534.648Si5-N14
CAS:<p>Si5-N14 is a key component of siloxane-linked lipid nanoparticles (SiLNP) with properties that enhance vascular repair and exhibit antitumor activity. In transgenic GFP mouse models, Si5-N14 mediates CRISPR-Cas9 editing. In Lewis lung carcinoma (LLC) tumor mouse models, it leads to the knockdown of vascular endothelial growth factor receptor 2 (VEGFR2), producing antitumor effects. Additionally, in mice with virus-induced lung injury, Si5-N14 facilitates the delivery of fibroblast growth factor-2 (FGF-2) mRNA, promoting vascular repair, oxygenation, and improved lung function. Si5-N14 shows potential for research in tumors, pneumonia, and cardiovascular diseases.</p>Fórmula:C78H160N6O5Si2Cor e Forma:SolidPeso molecular:1318.31EGFR-IN-78
<p>EGFR-IN-78 (compound A5), a 2-aminopyrimidine derivative, serves as a reversible EGFR C797S-TK inhibitor and an apoptosis inducer.</p>Fórmula:C23H32BrN7O2SPureza:98%Cor e Forma:SolidPeso molecular:550.51EGFR/COX-2-IN-1
<p>EGFR/COX-2-IN-1 is an EGFR/COX-2 inhibitor that effectively targets EGFRWT, EGFRT790M, COX-1, and COX-2 with IC50 values of 0.12, 0.076, 20.1, and 1.52 μM, respectively. It inhibits MCF-7, HT-29, and A-549 cells with IC50 values of 1.20, 5.14, and 14.81 μM, respectively. The compound induces apoptosis by upregulating Bax protein and downregulating Bcl-2 protein levels. Additionally, EGFR/COX-2-IN-1 significantly increases the proportion of cells in the G2/M phase in MCF-7 cells, demonstrating a broad-spectrum antitumor effect.</p>Fórmula:C20H17FN6O2S2Cor e Forma:SolidPeso molecular:456.52JAK1/STAT3-IN-1
<p>JAK1/STAT3-IN-1 (compound 4f) functions as an anti-atopic dermatitis (AD) agent by inhibiting the JAK1/STAT3 signaling pathway. It has an IC50 value of 2.17 μM for inhibiting NO production. Additionally, JAK1/STAT3-IN-1 improves skin conditions in AD-like mice by reducing inflammatory infiltration, suppressing the expression of p-JAK1/JAK1 and p-STAT3/STAT3, and alleviating the hyperimmune response induced by MC903 (Calcipotriol).</p>Fórmula:C30H33FN4O3SCor e Forma:SolidPeso molecular:548.67Multi-kinase-IN-5
<p>Multi-kinase-IN-5 (compound 15c) is a multi-kinase inhibitory agent that shows significant inhibition against a range of protein kinases including RET, KIT,</p>Fórmula:C19H15N5O2SCor e Forma:SolidPeso molecular:377.42JAK 3 inhibitor IV
CAS:<p>JAK 3 inhibitor IV (ZM 39923 hydrochloride) is a JAK1/3 inhibitor with pIC50 of 4.4/7.1, almost no activity to JAK2 and modestly potent to EGFR; also found to</p>Fórmula:C16H19NOPureza:98%Cor e Forma:SolidPeso molecular:241.33
